A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.


Updates from The Motley Fool

Latest updates on Immunomedics from Fool.com.  The Fool has written over 100 articles on Immunomedics.
Immunomedics' ASCO Letdown

A surprise cancellation of its presentation at ASCO caused Immunomedics shares to plummet last week.

This Week in Biotech

Four big rulings from the likes of the FDA, EMA, and USPTO, as well as one impressive clinical tr...

This Week in Biotech: Part 1

With 11 major biotech events this week, Part 1 of this two-part series looks at four FDA influenc...



Stock Performance

View Interactive IMMU Charts
Sponsored by

Key Data Points

Primary metrics and data points about Immunomedics.
Current Price: $5.44
Prev Close: $5.08
Open: $5.15
Bid: $5.44
Ask: $5.50
Day's Range: $5.15 - $5.46
52wk Range: $1.95 - $7.15
Volume: 1,944,966
Avg Vol 2,781,010
Market Cap: $577M
P/E (ttm): -7.06
EPS (ttm): ($0.72)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Immunomedics.
CAPS Rating 3 out of 5
 
216 Outperform
19 Underperform
CAPS All Stars
 
26 Outperform
3 Underperform

How do you think Immunomedics will perform against the market?



You pick for Immunomedics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Cynthia L. Sullivan, CEO

25% Approve

Based on 7 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Immunomedics.

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers